Shi Zhenjing, Luo Ya, Zhu Minghui, Zhou Yu, Zheng Bingru, Wu Daoyi, Wang Shuting, Xie Xiangbang, Lin Heping, Yu Xixiang
Department of Intervention, Third Affiliated Hospital of Wenzhou Medical University, Ruian, China.
Department of Hepatobiliary Surgery, Wenzhou People's Hospital, China.
Lab Med. 2019 Apr 8;50(2):150-157. doi: 10.1093/labmed/lmy055.
To determine the clinical relevance of long noncoding RNA (lncRNA) HAR1A and HAR1B expression in hepatocellular carcinoma (HCC).
In this study, we enrolled 50 cases of chronic hepatitis B (CHB) without cirrhosis, 50 cases of CHB and liver cirrhosis (LC), and 100 cases of HBV and HCC. The expression profiles of lncRNA HAR1A and HAR1B were analyzed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
The expression levels of HAR1A and HAR1B were significantly lower in the HCC group, compared with the CHB and LC groups (P <.01). HAR1A and HAR1B were negatively associated with histologic grade and TNM (tumor/nodes/metastasis) stage (all P <.05). Univariable multivariable analysis showed that decreased HAR1A (HR = 0.753, P = .02) and HAR1B (HR = 0.551, P = .01) levels were independent predictors for shorter overall survival (OS) in HCC.
Decreased HAR1A and HAR1B expression in HCC indicates poor prognosis.
确定长链非编码RNA（lncRNA）HAR1A和HAR1B表达在肝细胞癌（HCC）中的临床相关性。
在本研究中，我们纳入了50例无肝硬化的慢性乙型肝炎（CHB）患者、50例CHB合并肝硬化（LC）患者以及100例HBV相关HCC患者。采用逆转录定量聚合酶链反应（RT-qPCR）分析lncRNA HAR1A和HAR1B的表达谱。
与CHB组和LC组相比，HCC组中HAR1A和HAR1B的表达水平显著降低（P <.01）。HAR1A和HAR1B与组织学分级及TNM（肿瘤/淋巴结/转移）分期呈负相关（均P <.05）。单因素和多因素分析显示，HCC中HAR1A（HR = 0.753，P =.02）和HAR1B（HR = 0.551，P =.01）水平降低是总生存期（OS）较短的独立预测因素。
HCC中HAR1A和HAR1B表达降低提示预后不良。
